Public Consultation on the draft revised Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines

Public Submissions

The call for Submissions to the public consultation process for the draft revised PBAC Guidelines (Version 5.0) closed on 5 April 2016. The Department appreciates the contribution of all organisations and individuals who made a submission. 

The submissions have been provided to the Guidelines Review Steering Committee for consideration in the finalisation of the revised PBAC Guidelines.

Privacy

Unless otherwise requested, all submissions to the Review have been published on this page.

The Department of Health has not published submissions, or parts of submissions, that contain personal information, offensive language, potentially defamatory material or copyright infringing material.

Responsibility for copyright in submissions resides with the author(s), not with the Department of Health.

All submissions have been converted to Portable Document Format (PDF) for publication and may have a different appearance to the document that was submitted.

Your submission and contact details have been stored in accordance with the Australian Privacy Principles from Schedule 1 of the Privacy Amendment (Enhancing Privacy Principles) Act 2012 and the Archives Act 2012.  Should you have any concerns about the storage of your submission, or if you wish to gain access to make a correction, please email the PBS Post Market Review team. A copy of the Department’s privacy policy is available on request. If you wish to make a complaint about the handling of your private information, you may contact the Department of Health Privacy Contact Officer on 02 6289 5773 and, if unsatisfied with the response, you may submit a complaint to the Office of the Australian Information Commissioner.

Disclaimer

  • The views expressed in submissions published on this website are solely those of the contributing authors or organisations.
  • The Commonwealth accepts no responsibility for the completeness or accuracy of any information contained in the submissions.
  • The Commonwealth makes no representations about the suitability of the information for any particular purpose. Users of the information must make their own inquiries and assessments about those matters or seek independent advice.
  • Submissions are published on the understanding that the contributing authors or organisations have copyright in the submissions either by way of ownership or a licence. They retain their copyright, and by making submissions they licence the Commonwealth to publish the submissions, unless a party when making a submission has requested that it be kept confidential and the Commonwealth clearly agrees that the submission will be kept confidential. 
Table of Submissions
Submission Author Name Document Link Date Received
1 S & J Crowley Consulting, Noble Pharma Consulting, Shoten Consulting and Wonder Drug Consulting Submission 1 (PDF 97KB) 1/04/2016
2 Schizophrenia Fellowship of NSW Inc Submission 2 (PDF 817KB) 1/04/2016
3 Noble Pharma Consulting Submission 3 (PDF 25KB) 1/04/2016
4 Roche Products Submission 4 (PDF 838KB) 4/04/2016
5 Evaluator Group Not for publication 4/04/2016
6 Merck Serono Australia Submission 6 (PDF 635KB) 4/04/2016
7 Evaluator Group Not for publication 4/04/2016
8 Industry Organisation Not for publication 5/04/2016
9 HTAccess Consulting Submission 9 (PDF 235KB) 5/04/2016
10 Medicines Australia Submission 10 (PDF 356KB) 5/04/2016
11 SANE Australia Submission 11 (PDF 26KB) 5/04/2016
12 Evaluator Group Not for publication 5/04/2016
13 MSD Submission 13 (PDF 204KB) 5/04/2016
14 Shoten Consulting Submission 14 (PDF 2.4MB) 5/04/2016
15 Takeda Pharmaceuticals Australia Submission 15 (PDF 1.3MB) 5/04/2016
16 Metabolic Dietary Disorders Association Submission 16 (PDF 103KB) 5/04/2016
17 Mental Health Australia Submission 17 (PDF 489KB) 5/04/2016
18 NPS MedicineWise Submission 18 (PDF 143KB) 5/04/2016
19 Non-Government organisation Not for publication 5/04/2016
20 Non-Government organisation Not for publication 5/04/2016
21 Institute for Innovation and Valuation in Health Care Submission 21 (PDF 1.6MB) 5/04/2016
22 Bayer Australia Submission 22 (PDF 6.5MB) 5/04/2016
23 Lundbeck Australia Submission 23 (PDF 455KB) 5/04/2016
24 Evaluator Group Not for publication 5/04/2016
25 Pfizer Australia Submission 25 (PDF 4.1MB) 5/04/2016
26 Rare Voices Australia Submission 26 (PDF 190KB) 5/04/2016
27 Consumer Submission 27 (PDF 17KB) 5/04/2016
28 Sanofi Submission 28 (PDF 950KB) 5/04/2016
29 Optum on behalf of the Rare Disease Industry Working Group Submission 29 (PDF 131KB) 5/04/2016
30 Industry Organisation Not for publication 5/04/2016
31 Evaluator Group Not for publication 5/04/2016
32 Janssen Cilag Submission 32 (PDF 320KB) 5/04/2016
33 AstraZeneca Submission 33 (PDF 81KB) 5/04/2016
34 Novo Nordisk Pharmaceuticals Submission 34 (PDF 259KB) 5/04/2016
35 Vertex Pharmaceuticals Australia Submission 35 (PDF 312KB) 5/04/2016
36 Consumer Submission 36 (PDF 103KB) 5/04/2016
37 AbbVie Submission 37 (PDF 52KB) 5/04/2016
38 Optum Submission 38 (PDF 122KB) 5/04/2016
39 GlaxoSmithKline Submission 39 (PDF 3.4MB) 5/04/2016
40 Cancer Drugs Alliance Submission 40 (PDF 469KB) 6/04/2016
41 Royal Australian and New Zealand College of Psychiatrists Submission 41 (PDF 65KB) 6/04/2016
42 THEMA Consulting Submission 42 (PDF 179KB) 6/04/2016
43 Wonder Drug Consulting Submission 43 (PDF 357KB) 12/04/2016

 


Last updated
6 May 2016